Initial results from BEACON, a phase 1b/2a dose escalation study of the anti-c-Kit briquilimab antibody in adults with chronic spontaneous urticaria (CSU)

被引：0
|
作者：
Casale, Thomas [1 ]
Tucker, Edwin [2 ]
Yuan, Jinwei [2 ]
Adelman, Daniel [3 ]
Ku, David [2 ]
Marcantonio, Annette [2 ]
Carlos, Patricia [2 ]
Majeed, Sophia [2 ]
Pang, Wendy [2 ]
Maurer, Marcus [4 ]
Metz, Martin [5 ]
机构：
[1] Univ S Florida, Tampa, FL USA
[2] Jasper Therapeut, Redwood City, CA USA
[3] Univ Calif San Francisco, San Francisco, CA USA
[4] Charite, Berlin, Germany
[5] Charite Campus Mitte, Berlin, Germany
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2025年 / 155卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
L24
引用
收藏
页码：AB435 / AB435
页数：1
相关论文
共 50 条
  • [1] Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 b/g alone or in combination with pembrolizumab: Initial results from dose escalation
    Starodub, Alexander
    Powderly, John D.
    Kim, Sung-Bae
    Davar, Diwakar
    Hill, Andrew Graham
    Yeku, Oladapo O.
    Gabrail, Nashat Y.
    Krapp, Christian
    Pihl, Susanne
    Zhang, Ying
    Slavsky, Sibel
    Castro, Davis Y. Torrejon
    Uyei, Anne
    Singel, Stina Mui
    Kwatra, Vineet
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Dupilumab Improves Itch And Urticaria Activity In Patients With Chronic Spontaneous Urticaria: Pooled Results From Two Phase 3 Trials (LIBERTY-CSU CUPID Study A and Study C)
    Casale, Thomas
    Saini, Sarbjit
    Bernstein, Jonathan
    Gimenez-Arnau, Ana Maria
    Hayama, Koremasa
    Bauer, Deborah
    Amin, Nikhil
    Robinson, Lacey
    Dakin, Paula
    Laws, Elizabeth
    Radin, Allen
    Makhija, Melanie
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (02) : AB428 - AB428
  • [3] Results from a dose escalation phase 1b study of palbociclib and avelumab in advanced breast cancer in the PAveMenT Trial
    Okines, Alicia F.
    Moghadam, Houman
    Sparks, Laura
    Mohammed, Kabir
    Dunne, Kathryn
    Nerurkar, Ashutosh
    Osin, Peter
    Swift, Claire
    Sardinha, Ruth
    Turner, Nicholas
    CANCER RESEARCH, 2023, 83 (05)
  • [4] Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study
    Hari, Parameswaran N.
    Shain, Kenneth H.
    Voorhees, Peter M.
    Gabrail, Nashat
    Abidi, Muneer H.
    Zonder, Jeffrey
    Boccia, Ralph V.
    Richardson, Paul G.
    Neuman, Linda L.
    Dixon, Sandra J.
    Prada, Claudia Paba
    BLOOD, 2014, 124 (21)
  • [5] The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
    Martinez-Lopez, Joaquin
    Mustjoki, Satu
    Porkka, Kimmo
    Klisovic, Rebecca B.
    Wolf, Dominik
    Busque, Lambert
    Hernandez-Boluda, Juan Carlos
    Swanink, Rene
    Martin Regueira, Patricia
    Lipton, Jeffrey H.
    LEUKEMIA & LYMPHOMA, 2021, 62 (08) : 2040 - 2043
  • [6] Remibrutinib Improves Chronic Spontaneous Urticaria in Patients Irrespective of Previous Anti-IgE Treatment: Results From a Phase 2b Study
    Greiner, Alexander
    Guduri, Sridhar
    Leflein, Jeffrey
    Haemmerle, Sibylle
    Lheritier, Karine
    Walsh, Pauline
    Nikolaev, Ivan
    Gimenez-Arnau, Ana
    Maurer, Marcus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB131 - AB131
  • [7] A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma
    Gong, Jifang
    Guo, Ye
    Zhang, Yanqiao
    Ba, Yi
    Chen, Tong
    Li, Wei
    Zhou, Caicun
    Wang, Mengzhao
    Yang, Haiyan
    Zhou, Yuhong
    Cai, Qiqing
    Wang, Ziping
    Huang, Gang
    Zhang, Wei
    Su, Rila
    Cai, Zhongheng
    Yue, Zenglian
    Dou, Jinzhou
    Li, Peiqi
    Wu, Rachel
    Tse, Archie N.
    Shen, Lin
    TARGETED ONCOLOGY, 2024, 19 (05) : 723 - 733
  • [8] Phase 1b Dose Escalation Study of BI 836858 and Azacitidine in Previously Untreated AML: Results from Beat AML S2
    Blum, William
    Ruppert, Amy S.
    Mims, Alice S.
    Stein, Eytan M.
    Duong, Vu H.
    Odenike, Olatoyosi
    Patel, Prapti A.
    Kovacsovics, Tibor
    Heerema, Nyla A.
    Vergilio, Jo-Anne
    Rosenberg, Leonard
    Marcus, Sonja
    Stefanos, Mona
    Weiner, Howard
    Brandt, Jake
    Shoben, Abigail
    Druker, Brian J.
    Burd, Amy
    Levine, Ross L.
    Byrd, John C.
    Borate, Uma
    BLOOD, 2018, 132
  • [9] Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia
    Rogers, Kerry A.
    Huang, Ying
    Stark, Amy
    Awan, Farrukh T.
    Maddocks, Kami J.
    Woyach, Jennifer A.
    Whitlow, Thomas
    Byrd, John C.
    Jones, Jeffrey A.
    BLOOD, 2017, 130
  • [10] Initial results of a phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor
    Reesink, HW
    Zeuzem, S
    van Vliet, A
    McNair, L
    Purdy, S
    Chu, HM
    Jansen, PL
    GASTROENTEROLOGY, 2005, 128 (04) : A697 - A697
12345